Lilly Launches New Antidepressant Cymbalta(R)

[Guest guest]

I still can't believe they would release this drug.

http://biz./prnews/040824/detu008_1.html

Press Release Source: Eli Lilly and Company

Lilly Launches New Antidepressant Cymbalta®

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

ADVERTISEMENT

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing

portfolio of first-in-class and best-in-class pharmaceutical products by

applying the latest research from its own worldwide laboratories and from

collaborations with eminent scientific organizations. Headquartered in

Indianapolis, Ind., Lilly provides answers -- through medicines and information

-- for some of the world's most urgent medical needs. Additional information

about Lilly is available at www.lilly.com .

This press release contains forward-looking statements about the potential of

Cymbalta for the treatment of major depressive disorder and reflects Lilly's

current beliefs. However, as with any pharmaceutical product, there are

substantial risks and uncertainties in the process of development and

commercialization. There is no guarantee that the product will prove to be

commercially successful. For further discussion of these and other risks and

uncertainties, see Lilly's filings with the United States Securities and

Exchange Commission. Lilly undertakes no duty to update forward-looking

statements.

* (1) Tran PV, Bymaster FP, McNamara RK, et al. Dual Monoamine Modulation

for Improved Treatment of Major Depressive Disorder, J Clin Psychopharmacology,

2003; 23: 78-86

* (2) The Regents of the University of Michigan. Beyond Sadness. Bridging

the gap between emotional and physical symptoms of depression. Ann Arbor, MI,

2002

* (3) Nemeroff CB et al. Duloxetine for the Treatment of Major Depressive

Disorder. Psychoharmacol Bul. 2002; 36 (4):106-132.

* (4) Ohayon, M., et al. Using Chronic Pain to Predict Depressive Morbidity

in the General Population. Arch Gen Psychiatry 2003; 60: 39-47.

* (5) Poster presented at American Psychiatric Association annual meeting.

May 19, 2003. San Francisco, CA.

* (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

[Guest guest]

I still can't believe they would release this drug.

http://biz./prnews/040824/detu008_1.html

Press Release Source: Eli Lilly and Company

Lilly Launches New Antidepressant Cymbalta®

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

ADVERTISEMENT

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing

portfolio of first-in-class and best-in-class pharmaceutical products by

applying the latest research from its own worldwide laboratories and from

collaborations with eminent scientific organizations. Headquartered in

Indianapolis, Ind., Lilly provides answers -- through medicines and information

-- for some of the world's most urgent medical needs. Additional information

about Lilly is available at www.lilly.com .

This press release contains forward-looking statements about the potential of

Cymbalta for the treatment of major depressive disorder and reflects Lilly's

current beliefs. However, as with any pharmaceutical product, there are

substantial risks and uncertainties in the process of development and

commercialization. There is no guarantee that the product will prove to be

commercially successful. For further discussion of these and other risks and

uncertainties, see Lilly's filings with the United States Securities and

Exchange Commission. Lilly undertakes no duty to update forward-looking

statements.

* (1) Tran PV, Bymaster FP, McNamara RK, et al. Dual Monoamine Modulation

for Improved Treatment of Major Depressive Disorder, J Clin Psychopharmacology,

2003; 23: 78-86

* (2) The Regents of the University of Michigan. Beyond Sadness. Bridging

the gap between emotional and physical symptoms of depression. Ann Arbor, MI,

2002

* (3) Nemeroff CB et al. Duloxetine for the Treatment of Major Depressive

Disorder. Psychoharmacol Bul. 2002; 36 (4):106-132.

* (4) Ohayon, M., et al. Using Chronic Pain to Predict Depressive Morbidity

in the General Population. Arch Gen Psychiatry 2003; 60: 39-47.

* (5) Poster presented at American Psychiatric Association annual meeting.

May 19, 2003. San Francisco, CA.

* (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

[Guest guest]

I still can't believe they would release this drug.

http://biz./prnews/040824/detu008_1.html

Press Release Source: Eli Lilly and Company

Lilly Launches New Antidepressant Cymbalta®

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

ADVERTISEMENT

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing

portfolio of first-in-class and best-in-class pharmaceutical products by

applying the latest research from its own worldwide laboratories and from

collaborations with eminent scientific organizations. Headquartered in

Indianapolis, Ind., Lilly provides answers -- through medicines and information

-- for some of the world's most urgent medical needs. Additional information

about Lilly is available at www.lilly.com .

This press release contains forward-looking statements about the potential of

Cymbalta for the treatment of major depressive disorder and reflects Lilly's

current beliefs. However, as with any pharmaceutical product, there are

substantial risks and uncertainties in the process of development and

commercialization. There is no guarantee that the product will prove to be

commercially successful. For further discussion of these and other risks and

uncertainties, see Lilly's filings with the United States Securities and

Exchange Commission. Lilly undertakes no duty to update forward-looking

statements.

* (1) Tran PV, Bymaster FP, McNamara RK, et al. Dual Monoamine Modulation

for Improved Treatment of Major Depressive Disorder, J Clin Psychopharmacology,

2003; 23: 78-86

* (2) The Regents of the University of Michigan. Beyond Sadness. Bridging

the gap between emotional and physical symptoms of depression. Ann Arbor, MI,

2002

* (3) Nemeroff CB et al. Duloxetine for the Treatment of Major Depressive

Disorder. Psychoharmacol Bul. 2002; 36 (4):106-132.

* (4) Ohayon, M., et al. Using Chronic Pain to Predict Depressive Morbidity

in the General Population. Arch Gen Psychiatry 2003; 60: 39-47.

* (5) Poster presented at American Psychiatric Association annual meeting.

May 19, 2003. San Francisco, CA.

* (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

[Guest guest]

I still can't believe they would release this drug.

http://biz./prnews/040824/detu008_1.html

Press Release Source: Eli Lilly and Company

Lilly Launches New Antidepressant Cymbalta®

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

ADVERTISEMENT

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing

portfolio of first-in-class and best-in-class pharmaceutical products by

applying the latest research from its own worldwide laboratories and from

collaborations with eminent scientific organizations. Headquartered in

Indianapolis, Ind., Lilly provides answers -- through medicines and information

-- for some of the world's most urgent medical needs. Additional information

about Lilly is available at www.lilly.com .

This press release contains forward-looking statements about the potential of

Cymbalta for the treatment of major depressive disorder and reflects Lilly's

current beliefs. However, as with any pharmaceutical product, there are

substantial risks and uncertainties in the process of development and

commercialization. There is no guarantee that the product will prove to be

commercially successful. For further discussion of these and other risks and

uncertainties, see Lilly's filings with the United States Securities and

Exchange Commission. Lilly undertakes no duty to update forward-looking

statements.

* (1) Tran PV, Bymaster FP, McNamara RK, et al. Dual Monoamine Modulation

for Improved Treatment of Major Depressive Disorder, J Clin Psychopharmacology,

2003; 23: 78-86

* (2) The Regents of the University of Michigan. Beyond Sadness. Bridging

the gap between emotional and physical symptoms of depression. Ann Arbor, MI,

2002

* (3) Nemeroff CB et al. Duloxetine for the Treatment of Major Depressive

Disorder. Psychoharmacol Bul. 2002; 36 (4):106-132.

* (4) Ohayon, M., et al. Using Chronic Pain to Predict Depressive Morbidity

in the General Population. Arch Gen Psychiatry 2003; 60: 39-47.

* (5) Poster presented at American Psychiatric Association annual meeting.

May 19, 2003. San Francisco, CA.

* (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Tuesday August 24, 9:40 am ET

Long-awaited dual-reuptake inhibitor, now available in pharmacies, helps treat a

broad range of emotional and painful physical symptoms of Major Depressive

Disorder

INDIANAPOLIS, Aug. 24 /PRNewswire-FirstCall/ -- Cymbalta® (duloxetine HCl;

pronounced SIM-BALL-TA), a new treatment for major depression, is now available

by prescription in pharmacies across the United States, Eli Lilly and Company

(NYSE: LLY - News) announced today.

More than half of the nation's pharmacies, including drug store chains and

independents, have stocked Cymbalta and can begin filling prescriptions

immediately. Lilly expects more than 80 percent of pharmacies -- more than

44,000 stores -- to have Cymbalta on their shelves by Aug. 30. The U.S. Food and

Drug Administration approved Cymbalta, a balanced and potent selective serotonin

and norepinephrine reuptake inhibitor (SSNRI), on Aug. 3 for the treatment of

major depression.

" The availability of Cymbalta is a long-awaited milestone for patients and

physicians -- it's an effective antidepressant that helps treat both the

emotional and physical symptoms of depression, " said Lechleiter, executive

vice president of pharmaceutical products and corporate development at Lilly.

" It's the sort of breakthrough, born out of decades of investment and experience

in neuroscience, that is Lilly's hallmark. "

Today, only 25-35 percent of patients treated for depression in clinical studies

experience relief from all of their disease symptoms.(1) Patients who don't

become virtually symptom free are likely to suffer from depression again.

Neurotransmitters, chemicals that help nerve cells exchange messages, are

believed to help regulate a person's emotions and sensitivity to pain.

Scientists believe that if these neurotransmitters are out of balance, a person

may become depressed and be more likely to feel painful physical symptoms. The

combination of emotional and painful physical effects of depression can have a

tremendous negative impact on a person's quality of life.(2)

Randi Bradstreet, a participant in a Cymbalta clinical trial, had suffered for

years from the emotional and painful physical symptoms of depression.

" I started taking time off work a few years back because I was so depressed that

I couldn't function on my job. I had a lot of pain along with the depression and

it made it hard to do any physical activities that I needed to do with my job, "

Bradstreet said. " After I started taking Cymbalta, I began to feel like myself

again. That means that I'm happy. That I'm able to have fun with my friends and

family and that I can live a productive life. "

Duloxetine hydrochloride also is being studied for the treatment of stress

urinary incontinence and diabetic neuropathic pain, conditions believed to

respond to treatment with both serotonin and norepinephrine.

About Depression

Nearly 19 million Americans suffer from depression each year, making it one of

the leading causes of disability according to the World Health Organization.

Current medical literature suggests that patients who are successfully treated

for all their depressive symptoms, including both the emotional and painful

physical ones, may be more likely to achieve remission than those whose physical

symptoms are not alleviated.(1, 3, 4, 5)

Important Safety Information

Depression, as a disease, can be associated with periods when the symptoms can

worsen or thoughts of suicide can emerge. Patients and their families should

watch for these as well as for anxiety, agitation, panic, difficulty sleeping,

irritability, hostility, aggressiveness, impulsivity, restlessness, or

overexcitement and hyperactivity. Call the doctor if any of these are severe or

occur suddenly. Be especially observant at the initiation of antidepressant drug

therapy and whenever there is a change in dose.

Prescription Cymbalta is not for everyone. People who are allergic to duloxetine

hydrochloride or the other ingredients in Cymbalta should not take it. If you

are taking thioridazine or if you are taking or have recently taken a type of

antidepressant called a monoamine oxidase inhibitor (MAOI), you should not take

Cymbalta. It also should not be administered to patients with any hepatic

insufficiency, end-stage renal disease or uncontrolled, narrow-angle glaucoma.

Cymbalta ordinarily should not be prescribed to patients with substantial

alcohol use. Women who are pregnant should talk with their doctor before taking

Cymbalta. Nursing while taking Cymbalta is not recommended.

In clinical studies, the most common side effects were nausea, dry mouth,

constipation, decreased appetite, fatigue, sleepiness and increased sweating.

Most people were not bothered enough by side effects to stop taking Cymbalta.

Your doctor may periodically check your blood pressure. Don't stop taking

Cymbalta without talking to your doctor.

For full patient information, visit www.Cymbalta.com .